Portal de investigación
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
Fecha de publicación:
Autores organización
Autores
- Ríos R.
- Díaz L.
- Hernández-Gómez C.
- Radice M.
- Gales A.C.
- Castañeda Méndez P.
- Munita J.M.
- Martínez J.R.W.
Grupos de investigación
Resumen
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility. Copyright © 2022 Mojica, De La Cadena, Ríos, García-Betancur, Díaz, Reyes, Hernández-Gómez, Radice, Gales, Castañeda Méndez, Munita, Pallares, Martínez and Villegas.
Datos de la publicación
- ISSN/ISSNe:
- 1664-302X, 1664-302X
- Tipo:
- Article
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
Frontiers In Microbiology Frontiers Media S.A.
Citas Recibidas en Web of Science: 1
Citas Recibidas en Scopus: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- carbapenemase; cefepime; ceftazidime; ceftolozane plus tazobactam; piperacillin plus tazobactam; antibiotic resistance; antibiotic sensitivity; Article; bacterium identification; broth dilution; DNA extraction; matrix assisted laser desorption ionization time of flight mass spectrometry; minimum inhibitory concentration; multilocus sequence typing; nonhuman; pangenome; phylogenetic tree; Pseudomonas aeruginosa; real time polymerase chain reaction; South and Central America; tree of life; whole genome sequencing
Proyectos asociados
Dinámicas de colonización e infección por microorganismos multidrogorresistentes en pacientes de hospitales de alta complejidad
Investigador Principal: JINNETHE CRISTINA REYES MANRIQUE
UEB-2018-476 . 2018
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-585 . 2020
Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-586 . 2020
Citar la publicación
Mojica MF,De La Cadena E,Ríos R,García JC,Díaz L,Reyes J,Hernández C,Radice M,Gales AC,Castañeda P,Munita JM,Pallares CJ,Martínez JRW,Villegas MV. Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries. Front Microbiol. 2022. 13. 1035609. IF:5,200. (2).